Back

Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial

30 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Optimizing Management of Chronic CAD – Squeeze on Big Data for Additional Info Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Thomas Vanassche

University Hospitals (UZ) Leuven, Leuven (Belgium)

6 More presentations in this session

Presentation thumbnail
Time trends in risk factor control and use of secondary preventive medication among patients with myocardial infarction attending cardiac rehabilitation: data from the SWEDEHEART registry 2006-2017
Associate Professor M. Leosdottir (Malmo, SE)
Abstract Slides Video
Presentation thumbnail
Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach
Professor R. Storey (Sheffield, GB)
Abstract Slides Video
Presentation thumbnail
Identifying high thrombotic risk in atrial fibrillation patients undergoing percutaneous coronary intervention: is there a benefit of triple therapy?
Mr W. Bor (Nieuwegein, NL)
Abstract Slides Video
Presentation thumbnail
Ten-year all-cause death in elderly patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A prespecified subgroup analysis of the SYNTAX Extended Survival study
Doctor M. Ono (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Residual functional SYNTAX score by quantitative flow ratio and improvement of exercise capacity after revascularization in patients with stable ischemic heart disease
Doctor S. Lee (Gwangju, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Optimizing Management of Chronic CAD – Squeeze on Big Data for Additional Info

The Event

Event poster

ESC Congress 2020

30 August 2020 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources